Natalia Baran
Natalia Baran
Assistant Professor, University of Texas, MD Anderson Cancer Center
Verified email at
Cited by
Cited by
A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity
S Khan, X Zhang, D Lv, Q Zhang, Y He, P Zhang, X Liu, D Thummuri, ...
Nature medicine 25 (12), 1938-1947, 2019
Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells
M Daher, R Basar, E Gokdemir, N Baran, N Uprety, AK Nunez Cortes, ...
Blood, The Journal of the American Society of Hematology 137 (5), 624-636, 2021
Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypes
P Matre, J Velez, R Jacamo, Y Qi, X Su, T Cai, SM Chan, A Lodi, ...
Oncotarget 7 (48), 79722, 2016
Molecular pathways: hypoxia-activated prodrugs in cancer therapy
N Baran, M Konopleva
Clinical Cancer Research 23 (10), 2382-2390, 2017
Clonal selection and therapy resistance in acute leukaemias: mathematical modelling explains different proliferation patterns at diagnosis and relapse
T Stiehl, N Baran, AD Ho, A Marciniak-Czochra
Journal of The Royal Society Interface 11 (94), 20140079, 2014
Cell division patterns in acute myeloid leukemia stem-like cells determine clinical course: a model to predict patient survival
T Stiehl, N Baran, AD Ho, A Marciniak-Czochra
Cancer research 75 (6), 940-949, 2015
Combining AFM13, a bispecific CD30/CD16 antibody, with cytokine-activated blood and cord blood–derived NK cells facilitates CAR-like responses against CD30+ malignancies
LN Kerbauy, ND Marin, M Kaplan, PP Banerjee, MM Berrien-Elliott, ...
Clinical Cancer Research 27 (13), 3744-3756, 2021
Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials
TA Yap, N Daver, M Mahendra, J Zhang, C Kamiya-Matsuoka, ...
Nature medicine 29 (1), 115-126, 2023
Mitochondrial metabolism supports resistance to IDH mutant inhibitors in acute myeloid leukemia
L Stuani, M Sabatier, E Saland, G Cognet, N Poupin, C Bosc, FA Castelli, ...
Journal of Experimental Medicine 218 (5), e20200924, 2021
Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia
Q Zhang, B Riley-Gillis, L Han, Y Jia, A Lodi, H Zhang, S Ganesan, R Pan, ...
Signal transduction and targeted therapy 7 (1), 51, 2022
BETP degradation simultaneously targets acute myelogenous leukemic stem cells and the microenvironment
S Piya, H Mu, S Bhattacharya, PL Lorenzi, RE Davis, T McQueen, ...
The Journal of clinical investigation 129 (5), 1878-1894, 2019
The rarity of ALDH+ cells is the key to separation of normal versus leukemia stem cells by ALDH activity in AML patients
VT Hoang, EC Buss, W Wang, I Hoffmann, S Raffel, A Zepeda‐Moreno, ...
International journal of cancer 137 (3), 525-536, 2015
Exogenous mitochondrial transfer and endogenous mitochondrial fission facilitate AML resistance to OxPhos inhibition
K Saito, Q Zhang, H Yang, K Yamatani, T Ai, V Ruvolo, N Baran, T Cai, ...
Blood advances 5 (20), 4233-4255, 2021
Brasil da Costa, FH; Konopleva, M
SB Panina, N Baran
Kirienko, NV A mechanism for increased sensitivity of acute myeloid leukemia …, 2019
Utilizing synergistic potential of mitochondria-targeting drugs for leukemia therapy
SB Panina, J Pei, N Baran, M Konopleva, NV Kirienko
Frontiers in oncology 10, 435, 2020
A mechanism for increased sensitivity of acute myeloid leukemia to mitotoxic drugs
SB Panina, N Baran, FH Brasil da Costa, M Konopleva, NV Kirienko
Cell Death & Disease 10 (8), 617, 2019
TP53 in Acute Myeloid Leukemia: Molecular Aspects and Patterns of Mutation
B George, H Kantarjian, N Baran, JD Krocker, A Rios
International journal of molecular sciences 22 (19), 10782, 2021
Differences between healthy hematopoietic progenitors and leukemia cells with respect to CD44 mediated rolling versus adherence behavior on hyaluronic acid coated surfaces
M Hanke, I Hoffmann, C Christophis, M Schubert, VT Hoang, ...
Biomaterials 35 (5), 1411-1419, 2014
Inhibition of mitochondrial complex I reverses NOTCH1-driven metabolic reprogramming in T-cell acute lymphoblastic leukemia
N Baran, A Lodi, Y Dhungana, S Herbrich, M Collins, S Sweeney, ...
Nature communications 13 (1), 2801, 2022
Overexpression of CD200 is a stem cell-specific mechanism of immune evasion in AML
S Herbrich, N Baran, T Cai, C Weng, MJL Aitken, SM Post, J Henderson, ...
Journal for immunotherapy of cancer 9 (7), 2021
The system can't perform the operation now. Try again later.
Articles 1–20